Enclosed herewith intimation regarding Capacity Addition.
Press Release - Q1FY27
- Consolidated revenue 1.671bn, PAT 157m; Standalone revenue 1.467bn, PAT 141m
- Board approved capacity addition of 344 KL reactor at new greenfield unit in Dahej-III with 200 Cr investment over 21 months
- Capacity expansion to meet growing specialty chemicals demand
- Board approved re-appointment of MD and two Whole-time Directors for 3 years from Feb 2027
- Borrowing limit increased from 300 Cr to 1000 Cr, subject to member approval
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 TATVA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add TATVA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Tatva Chintan Pharma Chem Limited
Important.
The summary above is generated automatically from Tatva Chintan Pharma Chem Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.